Analysts Expect Breakeven For Verona Pharma Plc (NASDAQ:VRNA) Before Long
Analysts Expect Breakeven For Verona Pharma Plc (NASDAQ:VRNA) Before Long
With the business potentially at an important milestone, we thought we'd take a closer look at Verona Pharma plc's (NASDAQ:VRNA) future prospects. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's loss has recently broadened since it announced a US$54m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$125m, moving it further away from breakeven. Many investors are wondering about the rate at which Verona Pharma will turn a profit, with the big question being "when will the company breakeven?" We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
隨着業務可能進入一個重要的里程碑,我們認爲我們應該更加關注維羅納製藥股份有限公司(NASDAQ:VRNA)未來的前景。維羅納製藥股份有限公司是一家臨床階段的生物製藥公司,專注於開發和商業化治療呼吸系統疾病的療法,這些疾病存在未滿足的醫療需求。自最近的完整財年宣佈5400萬美元的虧損以來,該公司的虧損已經擴大,相比最新的過去12個月的虧損達到了1.25億美元,這將其進一步遠離盈虧平衡點。許多投資者想知道維羅納製藥何時能盈利,有一個重要的問題是「公司何時能盈虧平衡?」我們概述了行業分析師對該公司的預期、公司盈虧平衡的年份以及其隱含的增長率。
According to the 5 industry analysts covering Verona Pharma, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$60m in 2026. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 66% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根據覆蓋維羅納製藥的5位行業分析師的觀點,達成共識即將到來,他們預計公司將在2025年承擔最終的虧損,然後在2026年產生6000萬美元的正利潤。因此,該公司預計將於今天起2年左右實現盈虧平衡。爲了達到盈虧平衡的日期,我們計算了該公司必須以年度複合增長率增長的速度。結果表明,該公司預計年平均增長率將達到66%,這是非常樂觀的。如果這個速度被認爲過於激進,該公司的盈利時間可能比分析師預計要晚得多。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240810/0-a59b12aca7d59fad0797b36b9a12f24e-0-5d7d1a833853f8b77372a89005806285.png/big)
Underlying developments driving Verona Pharma's growth isn't the focus of this broad overview, but, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
推動維羅納製藥增長的潛在因素並不是這個廣泛概述的重點,但是需要考慮到製藥業通常根據產品開發階段有不規則的現金流動。這意味着,大規模的即將到來的增長率並非不尋常,因爲該公司正在開始收穫早期投資的成果。
One thing we'd like to point out is that The company has managed its capital judiciously, with debt making up 22% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
我們想指出的一件事是,該公司明智地管理了資本,債務佔股本的22%。這意味着,它主要從股本資金融資其運營,並且其低債務義務降低了投資虧損公司的風險。
Next Steps:
下一步:
This article is not intended to be a comprehensive analysis on Verona Pharma, so if you are interested in understanding the company at a deeper level, take a look at Verona Pharma's company page on Simply Wall St. We've also put together a list of key factors you should further research:
本文不旨在對維羅納製藥進行全面分析,因此,如果您有興趣深入了解該公司,請查看Simply Wall St上的維羅納製藥公司頁面。我們還彙總了您應進一步研究的關鍵因素列表:
- Historical Track Record: What has Verona Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Verona Pharma's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 歷史業績:維羅納製藥過去的表現如何?在過去的業績分析中進行更詳細的分析,並查看我們分析的免費視覺呈現,以獲得更清晰的了解。
- 管理團隊:經驗豐富的管理團隊能夠增加我們對業務的信心——請看看誰在維羅納製藥的董事會上,以及首席執行官的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。